A114450 Stock Overview
Green Lifescience Co., Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Green Lifescience Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,085.00 |
| 52 Week High | ₩3,543.75 |
| 52 Week Low | ₩1,781.00 |
| Beta | 1.18 |
| 1 Month Change | -14.55% |
| 3 Month Change | -0.24% |
| 1 Year Change | -29.44% |
| 3 Year Change | -77.85% |
| 5 Year Change | -33.33% |
| Change since IPO | -56.97% |
Recent News & Updates
Health Check: How Prudently Does Green Lifescience (KOSDAQ:114450) Use Debt?
Mar 26
KPX Lifescience.Co.Ltd (KOSDAQ:114450) Has Debt But No Earnings; Should You Worry?
Feb 22
Shareholder Returns
| A114450 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 13.0% | -0.8% | 2.2% |
| 1Y | -29.4% | 0.6% | 5.4% |
Return vs Industry: A114450 underperformed the KR Life Sciences industry which returned 2.2% over the past year.
Return vs Market: A114450 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A114450 volatility | |
|---|---|
| A114450 Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A114450 has not had significant price volatility in the past 3 months.
Volatility Over Time: A114450's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Jun-Yeong Yang | www.kpxls.com |
Green Lifescience Co., Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals and pesticides; and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, a piperacillin antibiotic intermediate; N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an antidepressant raw drug, and AM19, an antibiotic intermediate, as well as 1,1'-carbonyldiimidazole, which are coupling reagents used in pharmaceuticals.
Green Lifescience Co., Ltd. Fundamentals Summary
| A114450 fundamental statistics | |
|---|---|
| Market cap | ₩41.70b |
| Earnings (TTM) | -₩16.36b |
| Revenue (TTM) | ₩22.37b |
1.9x
P/S Ratio-2.5x
P/E RatioIs A114450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A114450 income statement (TTM) | |
|---|---|
| Revenue | ₩22.37b |
| Cost of Revenue | ₩24.68b |
| Gross Profit | -₩2.31b |
| Other Expenses | ₩14.04b |
| Earnings | -₩16.36b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -817.89 |
| Gross Margin | -10.34% |
| Net Profit Margin | -73.13% |
| Debt/Equity Ratio | 13.4% |
How did A114450 perform over the long term?
See historical performance and comparison